Prophylactic platelets in dengue: Survey responses highlight lack of an evidence base

James Whitehorn, Rosmari Rodriguez Roche, Maria Eugenia Guzman Siritt, Eric Martinez, Wilmar Gomez, Leonard Nainggolan, Ida Safitri Laksono, Ajay Mishra, Lucy C. Lum, Mohammed Abul Faiz, Amadou Sall, Joshua Dawurung, Alvaro Borges, Yee-Sin Leo, Lucille Blumberg, Daniel G. Bausch, Axel Kroeger, Olaf Horstick, Guy Thwaites, Heiman WertheimMattias Larsson, Tran Tinh M Hien, Rosanna W. Peeling, Bridget Wills, Cameron Simmons, Jeremy Farrar

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)


Dengue is the most important arboviral infection of humans. Thrombocytopenia is frequently observed in the course of infection and haemorrhage may occur in severe disease. The degree of thrombocytopenia correlates with the severity of infection, and may contribute to the risk of haemorrhage. As a result of this prophylactic platelet transfusions are sometimes advocated for the prevention of haemorrhage. There is currently no evidence to support this practice, and platelet transfusions are costly and sometimes harmful. We conducted a global survey to assess the different approaches to the use of platelets in dengue. Respondents were all physicians involved with the treatment of patients with dengue. Respondents were asked that their answers reflected what they would do if they were the treating physician. We received responses from 306 physicians from 20 different countries. The heterogeneity of the responses highlights the variation in clinical practice and lack of an evidence base in this area and underscores the importance of prospective clinical trials to address this key question in the clinical management of patients with dengue.

Original languageEnglish
Article numbere1716
JournalPLoS Neglected Tropical Diseases
Issue number6
Publication statusPublished - Jun 2012
Externally publishedYes

Cite this